Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 2 records in total 2
    records per page




    THE MUC5B PROMOTOR POLYMORPHISM ASSOCIATES WITH SEVERE COVID-19

    Authors: Coline H.M. van Moorsel; Joanne J van der Vis; Claudia Benschop; Henk J.T. Ruven; Marian Quanjel; Jan C Grutters

    doi:10.1101/2020.05.12.20099333 Date: 2020-05-16 Source: medRxiv

    Background Diversity in response to exposition to severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) is common and may be related to the innate immune response. The mucin MUC5B is an important component of the innate immune response and expression levels are associated with the MUC5B promoter polymorphism, rs35705950. The high expressing T-allele of rs35705950 is an accepted risk allele for a non-infectious aging lung disease MESHD called idiopathic pulmonary fibrosis MESHD pulmonary fibrosis HP ( IPF MESHD). However, given the theory of trade-offs in aging lung disease MESHD and the importance of high expression for an adequate immune response, we hypothesize that the T-allele is protective against severe coronavirus disease MESHD 2019 (COVID-19). Methods We collected demographics, radiology, survival data and MUC5B rs35705950 allele status for 108 patients requiring hospitalisation for COVID-19 at St Antonius Hospital in The Netherlands. For comparison of allele frequencies and allele carriership with a white control cohort, the patient cohort was divided in a white (n=83) and non-white cohort. Results The patients had a median age TRANS of 66 years and consisted predominantly of males TRANS (74%) and 23 patients (21%) died. The T-allele frequencies of rs35705950 in white patients was 0.04 which was significantly lower than the T-allele frequency of 0.10 in white controls (p= 0.02). Moreover, comparison of the number of carriers TRANS and non- carriers TRANS of the T allele showed that only 8.4% of patients carried the T-allele versus 18% of controls (p=0.029; OR= 0.41, CI=0.19-0.94). Conclusions The MUC5B rs35705950 promoter polymorphism associates with COVID-19. The risk allele (T) for IPF MESHD is protective against the development of severe COVID-19 disease. This is a further example of a trade-off between optimal expression levels in the respiratory system which associates with aging diseases. However, these results require further investigation.

    Pulmonary function of patients with 2019 novel coronavirus induced pneumonia HP pneumonia MESHD: A Retrospective Cohort Study

    Authors: Dongqing Lv; Xi Chen; Linghong Mao; Jiao Sun; Guixian Wu; Zhi Lin; Ronghai Lin; Jiansong Yu; Xiaomai Wu; Yongpo Jiang

    doi:10.21203/rs.3.rs-24303/v1 Date: 2020-04-21 Source: ResearchSquare

    Background: Pulmonary fibrosis HP Pulmonary fibrosis MESHD is a common complication in patients with viral pneumonia MESHD pneumonia HP, which causes restricted ventilation disorders MESHD and affects the prognosis of patients. However, the pulmonary function of patients with 2019 novel coronavirus (COVID-19)-induced pneumonia HP pneumonia MESHD has not yet been reported.Methods: A retrospective analysis of 137 patients with COVID-19-induced pneumonia HP pneumonia MESHD who were discharged from the Enze Hospital, Taizhou Enze Medical Center (Group), from January 31, 2020, to March 11, 2020. Follow-up occurred two weeks after hospital discharge, whereupon patients received a pulmonary function test. Results: Of the 137 patients who received a pulmonary function test two weeks after discharge, 51.8% were male TRANS, and the mean age TRANS was 47 years. Only 19.7% of the patients were identified as having severe novel coronavirus pneumonia MESHD pneumonia HP. The pulmonary function test showed that for a small number of patients ((FEV1/FVC)/% <70%,) the mean ICV and FVC was 2.4±0.7 L, 3.2±0.8 L, respectively. In severe cases, 88.9% of patients had an IVC <80% of the predicted value and 55.6% of patients had an FVC <80% of the predicted value. The MEF25, MEF50, and MEF75 <70% values were 55.6%, 40.7%, and 25.9%, respectively. In the non-severe group, 79.1% of patients has an IVC <80% of the predicted value, and 16.4% of patients had an FVC <80% of the predicted value. The mean MEF25, MEF50, and MEF75 <70% values were 57.3%, 30%, and 13.6%, respectively.Conclusions: In this study, the results suggest that the pulmonary function of patients with 2019 novel coronavirus (COVID-19)-induced pneumonia HP pneumonia MESHD manifested as restrictive ventilation disorder MESHD and small airway obstruction. The incidence was increased among critically ill patients.Trial registration number: ChiCTR2000029866.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.